Background
Methods
Patients
Surgical approach and postoperative adjuvant therapy
Follow-up
Statistical analysis
Results
Patients’ characteristics and types of surgery
N | NSR (n = 572) | CR (n = 152) | SPR (n = 113) |
P
| |
---|---|---|---|---|---|
Gender | 0.947 | ||||
Male | 668 | 457 (68.4%) | 120 (18.0%) | 91 (13.6%) | |
Female | 169 | 115 (68.0%) | 32 (18.9%) | 22(13.0%) | |
Age | 0.387 | ||||
< 60 years | 460 | 306 (66.5%) | 86 (18.7%) | 68 (14.8%) | |
≥ 60 years | 377 | 266 (70.6%) | 66 (17.5%) | 45 (11.9%) | |
Tumor size | < 0.001 | ||||
< 5 cm | 358 | 264 (73.7%) | 38 (10.6%) | 56 (15.6%) | |
≥ 5 cm | 479 | 308(64.3%) | 114 (23.8%) | 57 (11.9%) | |
Gastrectomy type | 0.106 | ||||
Proximal | 335 | 244 (72.8%) | 52 (15.5%) | 39 (11.6%) | |
Total | 502 | 328 (65.3%) | 100 (19.9%) | 74 (14.7%) | |
Greater curvature involved | < 0.001 | ||||
No | 617 | 445 (72.1%) | 91 (14.7%) | 81 (13.1%) | |
Yes | 220 | 127 (57.7%) | 61 (27.7%) | 32 (14.5%) | |
pT stage | < 0.001 | ||||
pT2 | 96 | 75 (78.1%) | 8 (8.3%) | 13 (13.5%) | |
pT3 | 282 | 212 (75.2%) | 28 (9.9%) | 42 (14.9%) | |
pT4a | 459 | 285 (62.1%) | 116 (25.3%) | 58 (12.6%) | |
pN stage | 0.003 | ||||
pN0 | 266 | 198 (74.4%) | 42 (15.8%) | 26 (9.8%) | |
pN1 | 149 | 106 (71.1%) | 31(20.8%) | 12 (8.1%) | |
pN2 | 180 | 122 (67.8%) | 26 (14.4%) | 32 (17.8%) | |
pN3a-3b | 242 | 146 (60.3%) | 53 (21.9%) | 43 (17.8%) | |
pTNM stage | < 0.001 | ||||
IB-IIA | 168 | 138 (82.1%) | 12 (7.1%) | 18 (10.7%) | |
IIB-IIIA | 432 | 293 (67.8%) | 87 (20.1%) | 52 (12.0%) | |
IIIB-IIIC | 237 | 141 (59.5%) | 53 (22.4%) | 43 (18.1%) | |
Bormann type | 0.475 | ||||
Bor 1–2 | 160 | 107 (66.9%) | 34 (21.3%) | 19 (11.9%) | |
Bor 3–4 | 677 | 465 (68.7%) | 118 (17.4%) | 94 (13.9%) |
Prognostic impact of No.10/No.11 LN metastases on APGC patients who underwent splenic hilar or splenic artery lymphadenectomy
Univariate analysis | Multivariate analysis | ||||
---|---|---|---|---|---|
5-year survival rate |
P
| RR | 95%CI |
P
| |
Gender | |||||
Male | 31.8% | ||||
Female | 27.8% | 0.564 | |||
Age | |||||
< 60 years | 31.2% | ||||
≥ 60 years | 30.6% | 0.843 | |||
Tumor size | |||||
< 5 cm | 41.5% | ||||
5-10 cm | 26.3% | 1.467 | 1.049–2.051 | 0.025 | |
≥ 10 cm | 21.1% | 0.001 | 1.515 | 0.969–2.369 | 0.069 |
Gastrectomy type | |||||
Proximal | 37.4% | ||||
Total | 27.6% | 0.047 | 1.008 | 0.731–1.391 | 0.961 |
pT stage | |||||
pT2 | 71.4% | ||||
pT3 | 37.1% | 1.399 | 0.657–2.980 | 0.384 | |
pT4a | 23.6% | < 0.001 | 1.860 | 0.904–3.826 | 0.092 |
pN stage | |||||
pN0 | 51.5% | ||||
pN1 | 41.9% | 0.983 | 0.589–1.642 | 0.949 | |
pN2 | 36.2% | 1.048 | 0.648–1.694 | 0.849 | |
pN3 | 8.3% | < 0.001 | 2.134 | 1.319–3.453 | 0.002 |
Bormann type | |||||
Bor 1–2 | 43.4% | ||||
Bor 3–4 | 27.8% | 0.007 | 1.142 | 0.766–1.704 | 0.515 |
Differentiation | |||||
Well | 36.0% | ||||
Poor | 27.2% | 0.025 | 1.164 | 0.862–1.572 | 0.323 |
Approach of lymphadenectomy | |||||
SPR | 36.3% | ||||
CR | 27.0% | 0.058 | |||
NO.10/11 lymphnode | |||||
Negative | 40.2% | ||||
Positive | 9.9% | < 0.001 | 1.745 | 1.241–2.454 | 0.001 |
Relationships between No.10/11 LN metastases and the clinicopathological factors of patients who underwent CR of the spleen and pancreas
Univariate analysis | Multivariate analysis | |||||
---|---|---|---|---|---|---|
No.10/11 - | No.10/11+ |
P
a
| RR | 95%CI |
P
b
| |
No.1/3 | ||||||
- | 91 (77.1%) | 27 (22.9%) | ||||
+ | 17 (50.0%) | 17 (55.0%) | 0.002 | 1.162 | 0.374–3.616 | 0.795 |
No.2/4 | ||||||
- | 84 (89.4%) | 10 (10.6%) | ||||
+ | 24 (41.4%) | 34 (58.6%) | < 0.001 | 6.780 | 2.316–19.846 | < 0.001 |
No. 5 | ||||||
- | 97 (72.9%) | 36 (27.1%) | ||||
+ | 11 (57.9%) | 8 (42.1%) | 0.176 | |||
No.6 | ||||||
- | 94 (74.6%) | 32 (25.4%) | ||||
+ | 14 (53.8%) | 12 (46.2%) | 0.034 | 2.615 | 0.735–9.306 | 0.138 |
No.7 | ||||||
- | 93 (78.8%) | 25 (21.2%) | ||||
+ | 15 (44.1%) | 19 (55.9%) | < 0.001 | 2.483 | 0.811–7.602 | 0.111 |
No.8 | ||||||
- | 99 (75.0%) | 33 (25.0%) | ||||
+ | 9 (45.0%) | 11 (55.0%) | 0.006 | 1.869 | 0.469–7.454 | 0.376 |
No. 9 | ||||||
- | 106 (75.2%) | 35 (24.8%) | ||||
+ | 2 (18.2%) | 9 (81.8%) | < 0.001 | 3.338 | 1.249–3.595 | 0.202 |
No. 12a | ||||||
- | 100 (71.4%) | 40 (28.6%) | ||||
+ | 8 (66.7%) | 4 (33.3%) | 0.727 | |||
Tumor size | ||||||
< 5 cm | 27 (71.1%) | 11 (28.9%) | ||||
5-10 cm | 64 (72.7%) | 24 (27.3%) | ||||
≥ 10 cm | 17 (65.4%) | 9 (34.6%) | 0.769 | |||
Bormann type | ||||||
Bor 1–2 | 28 (82.4%) | 6 (17.6%) | ||||
Bor 3 | 68 (73.1%) | 25 (26.9%) | 1.117 | 0.318–3.919 | 0.863 | |
Bor 4 | 12 (48.0%) | 13 (52.0%) | 0.013 | 2.126 | 0.417–10.846 | 0.365 |
Serosa involved | ||||||
No | 29 (80.6%) | 7 (19.4%) | ||||
Yes | 79 (68.1%) | 37 (31.9%) | 0.150 | |||
Differentiation | ||||||
Well | 55 (80.9%) | 13 (19.1%) | ||||
Poor | 53 (63.1%) | 31 (36.9%) | 0.016 | 1.313 | 0.465–3.707 | 0.607 |
Greater curvature involved | ||||||
No | 75 (82.4%) | 16 (17.6%) | ||||
Yes | 33 (54.1%) | 28 (45.9%) | < 0.001 | 2.963 | 1.112–7.897 | 0.030 |
Clinicopathological and survival features of SLNM risk grade in patients with NSR
SLNM low-mid risk n = (519) | SLNM high risk n = (53) |
P
| |
---|---|---|---|
Gender | 0.008 | ||
Male | 422(92.3%) | 35(7.7%) | |
Female | 97(84.3%) | 18(15.7%) | |
Age | 0.103 | ||
< 60 years | 272(88.9%) | 34(11.1%) | |
≥ 60 years | 247(92.9%) | 19(7.1%) | |
Tumor size | 0.672 | ||
< 5 cm | 241(91.3%) | 23(8.7%) | |
≥ 5 cm | 278(90.3%) | 30(9.7%) | |
Differentiation | 0.873 | ||
Well | 241(90.9%) | 24(9.1%) | |
Poor | 278(90.6%) | 29(9.4%) | |
Bormann type | 0.148 | ||
Bor 1–2 | 101(94.4%) | 6(5.6%) | |
Bor 3–4 | 418(89.9%) | 47(10.1%) | |
pT stage | 0.084 | ||
pT2 | 73(97.3%) | 2(2.7%) | |
pT3 | 188(88.7%) | 24(11.3%) | |
pT4a | 258(90.5%) | 27(9.5%) | |
pTNM stage | < 0.001 | ||
IB-IIA | 138(100%) | ||
IIB-IIIA | 274(93.5%) | 19(6.5%) | |
IIIB-IIIC | 107(75.9%) | 34(24.1%) |
Prognostic impact of the lymphadenectomy approach on patients with No.10/11 LN metastases
Operative features and postoperative complications in the NSR, CR, and SPR groups
NSR (n = 572) | CR (n = 152) | SPR (n = 113) |
P
| |
---|---|---|---|---|
Operation time (min) | 192 ± 13 | 241 ± 21 | 221 ± 7 | < 0.001a |
Intraoperativetransfusion | 154 (26.9%) | 68 (44.7%) | 36 (31.8%) | < 0.001b |
Postoperativehospital stay (days) | 12.63 ± 1.45 | 15.25 ± 2.86 | 12.86 ± 1.68 | < 0.001a |
Examined lymph nodes | 25.11 ± 13.71 | 28.38 ± 14.47 | 27.02 ± 11.32 | 0.018a |
Non-lethal Complication | 48 (8.4%) | 34 (22.4%) | 14 (12.4%) | < 0.001b |
Anastomotic leakage | 14 | 7 | 3 | |
Pancreas-related complications | 6 | 10 | 0 | |
Lung pleura- related complications | 7 | 6 | 2 | |
Wound complication | 5 | 2 | 3 | |
Postoperative ileus | 13 | 6 | 5 | |
Liver dysfunction | 3 | 3 | 0 | |
Mortality* | 3 | 9 | 1 | NS |
Postoperative chemotherapy | 0.118 | |||
Presence | 406(69.4%) | 96(16.4%) | 83(14.2%) | |
Absence | 166(65.9%) | 56(22.2%) | 30(11.9%) |